Frequency and severity of vasomotor symptoms reduced with fezolinetant versus placebo through 12 weeks

No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety

Authors say review findings are limited by heterogenous definitions of long COVID in published studies

Prevalence increased for self-reported diagnoses of migraine, hypertension, tendinitis, osteoarthritis, and endometriosis

Mean glycated hemoglobin level at 26 weeks increased with placebo, decreased with dulaglutide among youth with BMI >85th percentile

Risk for incidence of type 1 diabetes increased 25 percent in association with one increment in BMI standard deviation

Incidence rate of invasive disease-free survival events and incidence rates for death did not differ with addition of metformin, placebo

Maternal and neonatal outcomes examined in studies of gestational diabetes with and without insulin use

Eldecalcitol may have beneficial effect among those with lower level of basal insulin secretion

The once-weekly injection is approved as an addition to diet and exercise